I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

I am a healthcare professional in Canada

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Oncology Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

What's new

Sign up or login to unlock the full suite of MEDICALLY features
May 6 / Roche and Genentech
Cough, dyspnea, chest pain or a composite? Analysis of key symptoms in metastatic non-small cell lung cancer (mNSCLC) clinical trials
Lung cancer remains the leading cause of cancer deaths worldwide. Given its highly symptomatic nature, clinical trials often focus on composite patient-reported endpoints of metastatic non-small cell lung symptoms including chest pain, cough, dyspnea, arm and shoulder pain, and general pain. This poster reports on analyzing the key symptoms in metastatic non-small cell lung cancer clinical trials.
Oncology Non-Small Cell Lung Cancer ISPOR-2024

Sign up or login to unlock the full suite of MEDICALLY features
Apr 23 / Roche
Real-World Biomarker Test Utilization and Subsequent Treatment in Patients with Early-Stage Non-small Cell Lung Cancer in the United States, 2011-2021
Oncology Non-Small Cell Lung Cancer TUCSON-Symposium-2024

Sign up or login to unlock the full suite of MEDICALLY features
Apr 16 / Roche and Genentech
State-level opportunities for advancing biomarker testing in advanced non-small cell lung cancer (aNSCLC) patients with fully-insured commercial health plans
This poster shows the state-level opportunities for advancing biomarker testing in advanced non-small cell lung cancer (aNSCLC) patients with fully-insured commercial health plans.
Oncology Non-Small Cell Lung Cancer AMCP-2024

Sign up or login to unlock the full suite of MEDICALLY features
Apr 9 / Roche and Genentech
RNA-seq molecular subtypes and gene expression signatures in the phase 3 IMpower151 China study of 1L bevacizumab + pemetrexed/paclitaxel ± atezolizumab in metastatic NSCLC
IMpower151 (NCT04194203) is a Randomized, Double-Blind Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer. This poster reports on the exploratory biomarker analysis to characterize the molecular subtypes of Chinese metastatic nsqNSCLC by RNAseq and to explore the relationship between molecular subtype, predefined RNAseq signatures, PD-L1 status and clinical outcomes with ABCP and BCP.
Oncology Non-Small Cell Lung Cancer AACR-2024

Sign up or login to unlock the full suite of MEDICALLY features
Nov 4 / Roche and Genentech
IMpower110: Tertiary lymphoid structures (TLS) and clinical outcomes in advanced non-small cell lung cancer (NSCLC) treated with first-line atezolizumab or chemotherapy
IMpower110 was a randomized, open-label, Phase III study evaluating first-line atezolizumab vs chemotherapy in PD-L1–selected Stage IV NSCLC. This presentation reports exploratory results of pathologist-identified tertiary lymphoid structures status and its association with clinical outcomes in IMpower110.
Oncology Non-Small Cell Lung Cancer SITC-2023

Sign up or login to unlock the full suite of MEDICALLY features
Nov 3 / Roche and Genentech
TIGIT and PD-L1 co-blockade promotes functional differentiation and clonal expansion of antitumor CD8+ T cells resistant to exhaustion programming
Oncology Solid Tumours Non-Small Cell Lung Cancer SITC-2023
Treatment Management
  • Non-Small Cell Lung Cancer
7 results

Sign up or login to unlock the full suite of MEDICALLY features
Independent content
Sep 27 / Springer Healthcare
Managing ROS1 fusion-positive NSCLC in Europe and the USA
Luis Paz-Ares leads Jaime Schneider and Benjamin Besse in a discussion on the management of patients with ROS1 fusion-positive NSCLC in 2022.
Oncology Non-Small Cell Lung Cancer
Bookmark this
Share page

Sign up or login to unlock the full suite of MEDICALLY features
Independent content
May 19 / Springer Healthcare
The role of surgery in early-stage NSCLC management
Jessica Donington gives a surgeon’s perspective on the treatment of early-stage NSCLC in the era of targeted and immunotherapy options and the importance of helping patients to RIOT.
Oncology Non-Small Cell Lung Cancer
Bookmark this
Share page

Sign up or login to unlock the full suite of MEDICALLY features
Independent content
May 19 / Springer Healthcare
PD-L1 expression in early NSCLC: Interpreting the data so far
Heather Wakelee and Nasser Altorki discuss the current position on PD-L1 expression and immune checkpoint inhibition in early-stage, resectable NSCLC.
Oncology Non-Small Cell Lung Cancer
Bookmark this
Share page

Ask a question or share feedback

Get in touch

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.